Understanding How the Public Perceives and Values Pharmaceutical Quality

Event

FDA Convening

Understanding How the Public Perceives and Values Pharmaceutical Quality

Register

Ensuring the quality of pharmaceutical products is essential and is part of the mission of the U.S. Food and Drug Administration (FDA). When pharmaceutical products do not meet quality standards, patients can be harmed or drug shortages can arise. Stakeholders, including patients, providers, pharmacists, drug purchasers, and payers, may each consider quality when making decisions about pharmaceuticals; however, very little research explores the role of quality in stakeholder decision-making.

Morning

The morning public meeting, convened under a cooperative agreement between the Robert J. Margolis, MD, Center for Health Policy at Duke University in partnership with the FDA, provided an opportunity to explore and better understand how stakeholders perceive and value the quality of pharmaceutical products. Key FDA leadership and staff provided comments on the Agency’s current thinking and attendees were able to ask questions and engage with panelists. Topics for discussion included:

  • The importance of pharmaceutical quality;
  • The current state of pharmaceutical quality;
  • FDA’s role in regulating quality; and,
  • Stakeholder perceptions of pharmaceutical quality.

 

 Afternoon

Following the morning public workshop, the Robert J. Margolis, MD, Center for Health Policy at Duke University convened an afternoon private workshop, also under cooperative agreement with the FDA, to explore how stakeholders, including patients, providers, buyers and payers, perceive pharmaceutical quality and how these perceptions influence their decision-making. Feedback from the workshop will be used to help further inform FDA’s planning and engagement with the stakeholders to improve the quality of information available on pharmaceutical quality and its use in supporting the Agency’s mission of ensuring safe and effective medicines.

Funding for this meeting was made possible in part by a grant from the U.S. Food and Drug Administration. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the U.S. Food and Drug Administration nor does mention of trade names, commercial practices, or organizations imply endorsements.